Menu
Recruiting NCT06288256

Neurocognitive and Genomic Predictors of Persistent Pain and Opioid Misuse After Spine Surgery

Observational Lumbar Spine Pathology Elective Spine Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No Intervention.
Who it may be relevant to
Registry conditions: Lumbar Spine Pathology, Elective Spine Surgery. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Having spine surgery and recovery is a vulnerable period when opioid naive patients may transition into long-term use of opioids, and when previously opioid tolerant patients may be at risk to continue towards long-term opioid use and dependence. However, little is known about risk for developing opioid misuse, taking opioids differently than indicated or prescribed, and later OUD. This study addresses the question of whether behavior, cognitive features, and genomic markers can predict misuse of opioids, persistent pain and disability in individuals after spine surgery. To determine if impulsivity, inhibitory control, drug choice, and/or cognitive distortions predict opioid misuse and disability in spine surgery patients with differential gene expression. This is a prospective observational longitudinal study characterizing behavioral phenotypes in adults undergoing spine surgery using both patient-reported survey measures, cognitive testing and blood sampling. Outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and opioid misuse with spine related disability, and gene expression counts.

Interventions

  • Other No Intervention
    No Intervention

Primary outcome measures

  • Current Opioid Misuse Measure (COMM) Score [Time frame: Up to 12 months post-operatively]
Secondary outcome measures (1)
  • Numerical Rating Scale (NRS) Score [Time frame: Up to 12 months post-operatively]

Eligibility criteria

Inclusion criteria

  • Age over 18
  • With diagnoses of lumbar, cervical or thoracic spine pathology, scheduled to undergo elective spine surgery with or without instrumentation

Exclusion criteria

  • Severe psychiatric condition interfering with study participation Any major cardiac, pulmonary, renal, infectious, hepatic condition that interferes with study participation
  • Polytrauma
  • Prolonged hospitalization (>10days)
  • Pregnancy
  • Known surgery cancellation within study period

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Mount Sinai Spine Center — New York

Identifiers

NCT: NCT06288256 · STUDY-22-01390

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗